About ReShape Lifesciences, Inc. - Common Stock (RSLS)
Reshape Lifesciences Inc is a biotechnology company focused on developing innovative medical technologies and solutions for weight management and obesity-related health issues. The company's primary aim is to enhance patient outcomes through its proprietary products, which include minimally invasive procedures designed to aid in weight loss and promote healthier lifestyles. By leveraging advanced engineering and clinical expertise, Reshape Lifesciences seeks to address the growing global health crisis associated with obesity and its complications, ultimately striving to empower individuals to take control of their health through effective interventions. Read More
Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
NEW YORK, March 23, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of ReShape Lifesciences Inc. (the “Company”) (NasdaqCM: RSLS) and Vyome Therapeutics, Inc. Under the terms of the Proposed Transaction, ReShape shareholders will own approximately 11.1% of the combined company immediately following the closing of the merger, subject to adjustment based on ReShape’s actual net cash at closing compared to a target net cash amount of $5 million. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fair to ReShape shareholders.
Speculation over an impending reverse merger, a Phase 2 trial announcement, comments about upcoming cancer screening tests, a Medicare business deal, and an obesity drug partnership sparked buzz among Stocktwits users for the week ended March 7, 2025.
